Healthcare

Current market conditions such as regulations and mergers or acquisitions make improving compliance and manufacturing efficiency while driving to grow revenue and margins difficult. 

When most supermarket chains were facing a downtrend of their annual sales revenue, Carrefour Taiwan bagged a 10% growth rate in annual sales revenue in 2016, and becoming Top 5 in the region on Carrefour’s global list.

Purpose-built SSU solutions track clinical trial operations using much needed standardized performance metrics.

When you’re capturing millions upon millions of documents for global clients in healthcare, insurance, banking, finance, and other industries, you need world-class scanning technology to power your enterprise. For this business-process services provider, flawless performance and reliability are essential — as digital payments, claims processing, benefit administration, customer care, and distributed learning are just some of the services delivered.

Numerous changes in the pharmaceutical industry have affected the nature of clinical trials, which in turn have led to the evolution of systems used for the supply of clinical trial materials.

For a child experiencing psychological trauma due to family breakdown, the wheels of social services bureaucracies cannot move fast enough. Quite literally, a child in immediate need cannot wait — whether for the comforts of peanut butter or pizza, or a secure place to call home. This is the primary concern of KVC Health Systems, a private, nonprofit behavioral healthcare and child welfare headquartered in the greater Kansas City area.

There is a dazzling array of quality initiatives within the clinical trials sector all looking to move the needle from paper-based methods or single point solutions to a more integrated, non-siloed approach to study conduct. These efforts, may be rooted, at least somewhat, in work started nearly 20 years when the Institute of Medicine published To Err is Human, a call-to-action to improve safety in our healthcare system by linking it to greater quality. That seminal work was followed by various reports recognizing the urgent need to transform the clinical trials enterprise by focusing more intently on quality, which leads us to today’s sharp focus on this subject.

The push to deliver greater value is prompting healthcare organizations to closely examine their clinical and financial processes in search of ways to boost efficiency, improve accuracy, and elevate the patient experience. With this in mind, First Care Clinic, a federally qualified health center and level 3 patient centered medical home located in rural Kansas, set out to retool one of its critical processes — the patient care visit.

In the continuing effort to increase quality and decrease costs, health plans and providers are shifting from volume-based care (fee for service) to a value-based reimbursement structure (fee for value). Value-based reimbursement promises benefits to patients, providers, and health plans, as it encourages delivery of high quality care at the lowest cost, largely by improving clinical and administrative efficiency.

At University of Chicago Medicine, we’ve been on a journey to make our experience match our science. One of the key efforts on that journey was to introduce iPad-based rounding as a tool to help nurse leaders identify and solve any patient or family concerns quickly and efficiently, as well as to recognize nurses and other staff members for excellence. We also wanted to capture patient comments in a way that would help inform system-level improvement efforts.

A growing number of healthcare payers are seizing the opportunity to optimize their population health management (PHM) programs for seriously ill patients. By Greer Myers, President, Turn-Key Health

The number of clinical trials conducted per year, their complexity, and the percentage of trials experiencing delays have all been increasing in recent years, accompanied by spiraling costs and lengthening trial times. This trend, along with a rise in overall drug development costs, has been occurring at a time when governments, payers, and patients are demanding that pharmaceutical manufacturers provide evidence of measurable value for any new treatment.